StockData
Cibus, Inc. logo

Cibus, Inc. (CBUS) company profile

CBUSNasdaqAgricultural ChemicalsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30206% above fair value
$1.39+0.19 (+15.83%)

Close on Nov 17, 2026Market cap $106.24MP/E –Yield –

About Cibus

Agricultural Chemicals, SIC 2870

Cibus develops proprietary plant traits using precision gene editing technologies, particularly its Rapid Trait Development System and Trait Machine process. The enterprise focuses primarily on licensing productivity traits, such as weed management and disease resistance, directly into seed companies' elite germplasm for royalty fees. Key agricultural programs target rice herbicide tolerance alongside trait initiatives across crops like canola, soybean, and wheat. Beyond core crop genetics, the organization maintains a sustainable ingredients line producing bio-based fragrance products through yeast fermentation for consumer packaged goods companies. Its customer base includes global seed producers and multinational corporate partners.

The entity maintains core operational activities and headquarters in San Diego, California, having streamlined staff and wound down a facility in Roseville, Minnesota. Its geographic footprint and commercial relationships span seed partners and field research programs across the United States, Latin America, Europe, the United Kingdom, and India.

Summary of the business section of Cibus's latest annual report, written by StockData.

Company profile

Company

Legal name
Cibus, Inc.
Headquarters
San Diego, CA
Address
6455 Nancy Ridge Drive 92121
Phone
(858) 450-0008
Website
cibus.com
Employees
118, Dec 31, 2025
Industry
Agricultural Chemicals
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BDO USA, P.C., San Diego, California

Stock & identifiers

Ticker
CBUS
Former tickers
CLXT until Jun 1, 2023
Exchange
Nasdaq
IPO date
Jul 21, 2017
Shares outstanding
76M, Aug 7, 2026
Public float
$47.16M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-5 reverse, Jun 1, 2023; 1-for-10 reverse, Apr 25, 2023
SEC CIK
1705843
CUSIP
17166A101
ISIN
US17166A1016
FIGI
BBG00H1CJS11
Share class FIGI
BBG00H1CJSR3
EIN
27-1967997

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Carlo BroosCFO225,935
Jason StokesCAO, Gen Csl & Corp Secy164,346
Noel SauerSr VP, Research138,040
Craig WichnerCEO894,309
Peter BeethamInterim CEO, Pres & COO686,825
Gregory Francis William GocalChief Scientific Officer & EVP422,890
Rory B. RiggsDirector14,982,312
Kimberly Ann BoxDirector0
August J. MorettiDirector0
Mark Terrence FinnDirector2,951,382
Jean-Pierre Jules LehmannDirector2,450,975
Gerhard PranteDirector104,945
Thomas UrbanDirector64,748
Keith Allen WalkerDirector98,701

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Peter Beetham
$1.36M$1.17M$705.22K$24–
FY2025
Rory Riggs
$302.36K$200.10K$705.22K$24–
FY2024$500.01K-$1.24M$525.75K$38–
FY2023
Michael Carr
$1.16M$1.47M$756.80K$269–
FY2023
Rory Riggs
$292.31K-$1.84M$756.80K$269–
FY2022$1.51M-$322.67K$856.10K$7–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Peter Beetham
Interim Chief Executive Officer, President, Chief Operating Officer, and Director
$630.58K–$276.10K$457.67K–$1.36M+173%
Rory Riggs
Former Chief Executive Officer
$161.54K––$89.94K$50.88K$302.36K-40%
Greg Gocal
Chief Scientific Officer and Executive Vice President
$455.02K$132.00K$218.40K––$805.42K+77%
Jason Stokes
Chief Administrative Officer, General Counsel and Corporate Secretary
$439.71K–$62.15K$103.15K–$605.01K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 21, 2017
Offer price
$8.00
Securities offered
7,000,000
Gross proceeds
$56.00M
Exchange
Nasdaq
First trading day
Jul 20, 2017
First-day close
$11.25+40.6%
Lock-up ends (est.)
Jan 16, 2018

“Our shares of common stock have been approved for listing on the NASDAQ Global Market (the “NASDAQ”) under the symbol “ CLXT .” The initial public offering price is $8.00 per share of common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, Cibus had 118 full-time employees, including a total of 29 employees with Ph.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?